High-dose Etoposide Could Discriminate Patients With Refractory/Relapsed Lymphoma Benefit From APBSCT

Yang Jun

Status: Completed

Conditions: Lymphoma

Treatments: Drug: high-dose etoposide

Study type: Observational

Funder types: Other

Identifiers

NCT03130582

2015KY143

Details and patient eligibility

About

patients with refractory /relapsed lymphoma received high-dose etoposide for hematopoietic stem cell (HSC) mobilization.All patients received high-dose etoposide 20-25 mg/kg/d intravenously for two consecutive days followed by rhG-CSF10ug/kg/day subcutaneously at 48 hours after chemotherapy; rhG-CSF was continued until the end of harvesting for HSCs/HPCs. Peripheral blood counts were performed daily for all patients following the initiating of rhG-CSF. Leukapheresis was performed when peripheral blood white blood count exceeded 4×109/L with blood cell The harvested cells reached at least 2*108/kg for mononuclear cells and/or 2*106/kg for CD34+ cells with once to twice leukapheresis. The final product was kept frozen in liquid nitrogen.Auto-PBSCT

Enrollment: 88 patients

Sex: All

Ages: 16 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• relapsed/refractory lymphoma ,siut APBSCT

Exclusion criteria

• bone marrow without involvement by lymphoma cells

Trial design

88 participants in 2 patient groups

Disease status at mobilization PR

Treatment:

Drug: high-dose etoposide

Disease status at mobilization PD

Treatment:

Drug: high-dose etoposide